NATRILIX® SR 1.5mg Tablets indapamide
Prescribing Information
Refer to Summary of Product Characteristics (SPC) before prescribing.

Presentation: Prolonged release film-coated tablets each containing 1.5mg indapamide.
Indication: Essential hypertension. Dosage and Administration: Adults: The dosage is one tablet daily, preferably in the morning. Indapamide reduces left ventricular hypertrophy. It has been demonstrated that in the short-, medium- and long-term, in hypertensive patients, indapamide: • does not interfere with lipid metabolism: triglycerides, LDL-cholesterol and HDL cholesterol • does not interfere with carbohydrate metabolism, even in diabetic hypertensive patients. Elderly: can be treated with Natrilix SR when renal function is normal or only minimally impaired. Paediatric population: not recommended for use due to a lack of data on safety and efficacy in this group. Contraindications: Hypersensitivity to indapamide, to other sulfonamides or to any of the excipients; severe renal failure; hepatic encephalopathy or severe impairment of liver function; hypokalaemia. Precautions: In hepatic impairment, if encephalopathy occurs, stop Natrilix SR immediately. If photosensitivity occurs during treatment, stop Natrilix SR. Not to be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Plasma sodium should be measured before and at intervals during treatment. Plasma potassium should be monitored closely from the first week of treatment in patients in whom hypokalaemia presents a risk. Transitory rise in plasma calcium may occur. Gout attacks may increase in hyperuricemic patients. Reduction in glomerular filtration due to hypovolaemia may worsen renal insufficiency. Pregnancy/Breast-feeding: Not recommended. Interactions: Serum lithium concentrations may rise during lithium therapy; combination not recommended. Caution required in co-administration with drugs prolonging the QT interval or causing torsade de pointes, NSAIDs, high dose salicylates, ACE inhibitors, compounds causing hypokalaemia, baclofen, digitalis. Careful consideration required in co-administration with potassium-sparing diuretics, metformin, iodinated contrast media, imipramine-like antidepressants or neuroleptics, calcium, ciclosporin, tacrolimus and IV corticosteroids or tetracosactide. Side Effects: Hypokalaemia, maculopapular rash. Very rarely, hypotension, arrhythmias, blood dyscrasias, pancreatitis, renal failure, abnormal hepatic function, angioneurotic oedema, toxic epidermic necrolysis, Steven-Johnson syndrome, hypercalcemia. Frequency not known: syncope, torsades de pointes, QT prolongation, hepatitis, elevated liver enzymes. Consult SPC for full list of side effects. NHS Price: £3.40 per pack of 30 tablets. Legal Category: POM. Product Licence Number: 5815/0010. Further Information: Servier Laboratories Ltd, Rowley, Wexham Springs, Slough SL3 6PJ Tel (01753) 666409. Date of Revision: February 2016.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Servier Laboratories Ltd. Tel (01753) 666409